{"id":"erythropoietin-beta","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thromboembolism"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"<1","effect":"Pure red cell aplasia"}]},"_chembl":{"chemblId":"CHEMBL2108888","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Erythropoietin beta is a recombinant form of the naturally occurring hormone erythropoietin (EPO), which binds to the erythropoietin receptor on erythroid progenitor cells. This binding activates intracellular signaling pathways that promote proliferation, differentiation, and maturation of red blood cell precursors. The result is increased hemoglobin and hematocrit levels, improving oxygen-carrying capacity of blood.","oneSentence":"Erythropoietin beta stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:28.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Chemotherapy-induced anemia"},{"name":"Anemia in patients with cancer"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT01732146","phase":"PHASE3","title":"Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-03-28","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":120},{"nctId":"NCT05891249","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-05","conditions":"Anemia","enrollment":85},{"nctId":"NCT00396435","phase":"PHASE4","title":"Correction of Anaemia and Progression of Renal Failure on Transplanted Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2004-04","conditions":"Anaemia, Renal Transplantation, Kidney Failure","enrollment":128},{"nctId":"NCT00661388","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":75},{"nctId":"NCT00560404","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":233},{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT02876211","phase":"PHASE4","title":"Paricalcitol Improves Anemia of Inflammation","status":"TERMINATED","sponsor":"Hospital Son Espases","startDate":"2014-12","conditions":"Anemia","enrollment":19},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT00875004","phase":"NA","title":"Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2007-12-07","conditions":"Anemia, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":27},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT02550054","phase":"PHASE2","title":"Erythropoietin in Premature Infants to Prevent Encephalopathy","status":"TERMINATED","sponsor":"Children's Hospital of Fudan University","startDate":"2015-09-08","conditions":"Premature Infant","enrollment":58},{"nctId":"NCT04155125","phase":"PHASE3","title":"A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient","status":"COMPLETED","sponsor":"PT Kalbe Genexine Biologics","startDate":"2020-07-02","conditions":"Anaemia Associated With Chronic Kidney Disease","enrollment":391},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT03552393","phase":"PHASE2","title":"Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-03","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT02745990","phase":"NA","title":"Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants","status":"UNKNOWN","sponsor":"Huiqing Sun","startDate":"2016-05","conditions":"Developmental Disabilities","enrollment":440},{"nctId":"NCT02791763","phase":"PHASE3","title":"Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-06","conditions":"Anaemia","enrollment":355},{"nctId":"NCT02707757","phase":"PHASE4","title":"Treatment Response in Dialysis Anaemia","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2015-07","conditions":"Anaemia, Haemodialysis","enrollment":197},{"nctId":"NCT03519243","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-10-24","conditions":"Anemia","enrollment":75},{"nctId":"NCT03914690","phase":"PHASE2","title":"Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage","status":"COMPLETED","sponsor":"Zhengzhou University","startDate":"2014-07","conditions":"Premature Infants","enrollment":316},{"nctId":"NCT03803514","phase":"","title":"Effect of rEPO in FGF23 in ESRD Patients","status":"COMPLETED","sponsor":"University of Chile","startDate":"2017-08-15","conditions":"Anemia, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT02145026","phase":"PHASE4","title":"A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-06","conditions":"Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT03214627","phase":"NA","title":"Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial","status":"TERMINATED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2018-12-10","conditions":"Anemia, End Stage Renal Disease","enrollment":88},{"nctId":"NCT03408639","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-06-22","conditions":"Anemia in End-Stage Renal Disease","enrollment":156},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":201},{"nctId":"NCT02064426","phase":"PHASE2","title":"Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-13","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":88},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT01902628","phase":"","title":"OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-15","conditions":"Anemia","enrollment":437},{"nctId":"NCT01756612","phase":"","title":"A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11-21","conditions":"Renal Anemia of Chronic Kidney Disease","enrollment":551},{"nctId":"NCT03658876","phase":"PHASE4","title":"Predictors of Response to Iron and Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-06-03","conditions":"Renal Failure Chronic, Anemia","enrollment":197},{"nctId":"NCT02731469","phase":"PHASE1","title":"Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06-15","conditions":"Reticulocyte Count","enrollment":45},{"nctId":"NCT01519947","phase":"PHASE4","title":"A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":87},{"nctId":"NCT03919500","phase":"PHASE2","title":"Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis","status":"COMPLETED","sponsor":"Zhengzhou University","startDate":"2014-01","conditions":"Premature Infant","enrollment":1285},{"nctId":"NCT01817699","phase":"PHASE4","title":"Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"CANDLE-KIT Trial Study Group","startDate":"2013-04","conditions":"Kidney Transplantation, Anemia, Vitamin D Deficiency","enrollment":161},{"nctId":"NCT02076373","phase":"PHASE3","title":"Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2014-03","conditions":"Intraventricular Hemorrhage of Prematurity","enrollment":120},{"nctId":"NCT02761642","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02-29","conditions":"Anemia","enrollment":200},{"nctId":"NCT01191983","phase":"PHASE4","title":"A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08-13","conditions":"Anemia","enrollment":102},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT02950857","phase":"PHASE1","title":"A Study of EPEG in Beta Thalassemia Patients","status":"COMPLETED","sponsor":"Prolong Pharmaceuticals","startDate":"2017-06-28","conditions":"Beta-Thalassemia","enrollment":6},{"nctId":"NCT00048048","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":65},{"nctId":"NCT00551603","phase":"PHASE4","title":"Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules","status":"WITHDRAWN","sponsor":"Anemia Working Group Romania","startDate":"2006-07","conditions":"Bio-Equivalency of 2 Treatment Schedules in HD Patients","enrollment":""},{"nctId":"NCT00737464","phase":"PHASE4","title":"A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08-26","conditions":"Anemia","enrollment":132},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT01066000","phase":"PHASE4","title":"A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Anemia","enrollment":33},{"nctId":"NCT02044653","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Genexine, Inc.","startDate":"2014-04-15","conditions":"Anemia, Chronic Kidney Disease","enrollment":257},{"nctId":"NCT03110341","phase":"PHASE3","title":"Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-04-10","conditions":"Premature Infants, Intracranial Hemorrhages, Periventricular Leukomalacia","enrollment":400},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00922116","phase":"PHASE4","title":"A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia","enrollment":191},{"nctId":"NCT01379963","phase":"","title":"A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":780},{"nctId":"NCT01417377","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-31","conditions":"Anemia","enrollment":22},{"nctId":"NCT01342640","phase":"PHASE4","title":"A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-18","conditions":"Anemia","enrollment":70},{"nctId":"NCT01677767","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-30","conditions":"Anemia","enrollment":127},{"nctId":"NCT00642668","phase":"PHASE4","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06-30","conditions":"Anemia","enrollment":35},{"nctId":"NCT01318512","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Kidney Disease, Chronic","enrollment":340},{"nctId":"NCT01940484","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08-31","conditions":"Anemia","enrollment":98},{"nctId":"NCT00776425","phase":"PHASE4","title":"A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Anemia","enrollment":117},{"nctId":"NCT02596945","phase":"","title":"Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07-31","conditions":"Renal Impairment, Renal Anemia of Chronic Kidney Disease","enrollment":223},{"nctId":"NCT00737477","phase":"PHASE3","title":"A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-30","conditions":"Anemia","enrollment":96},{"nctId":"NCT02538107","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09-30","conditions":"Anemia, Kidney Transplantation","enrollment":290},{"nctId":"NCT02547454","phase":"","title":"An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-31","conditions":"Kidney Disease, Chronic","enrollment":393},{"nctId":"NCT02238080","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Chronic Kidney Diseases","enrollment":197},{"nctId":"NCT01194154","phase":"PHASE2","title":"A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Kidney Disease, Chronic","enrollment":241},{"nctId":"NCT02767765","phase":"PHASE3","title":"A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-06","conditions":"Anemia","enrollment":61},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT00048035","phase":"PHASE2","title":"A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":91},{"nctId":"NCT00576628","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Anemia","enrollment":133},{"nctId":"NCT01718379","phase":"PHASE2","title":"Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2010-07","conditions":"Myelodysplastic Syndromes","enrollment":132},{"nctId":"NCT00576602","phase":"PHASE4","title":"A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":1},{"nctId":"NCT02608060","phase":"PHASE4","title":"A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":4},{"nctId":"NCT01309295","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Anemia, Kidney Disease, Chronic","enrollment":250},{"nctId":"NCT02564094","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Anemia","enrollment":54},{"nctId":"NCT00081471","phase":"PHASE3","title":"A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":324},{"nctId":"NCT02569515","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":58},{"nctId":"NCT00077597","phase":"PHASE3","title":"A Study of Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":182},{"nctId":"NCT00081484","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":336},{"nctId":"NCT02624141","phase":"PHASE4","title":"A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Anemia","enrollment":10},{"nctId":"NCT00773331","phase":"PHASE3","title":"A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Anemia","enrollment":281},{"nctId":"NCT00922610","phase":"PHASE4","title":"A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":28},{"nctId":"NCT00442793","phase":"PHASE3","title":"A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Anemia","enrollment":265},{"nctId":"NCT01974271","phase":"","title":"An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Anemia","enrollment":661},{"nctId":"NCT00377481","phase":"PHASE4","title":"COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":48},{"nctId":"NCT01213485","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Anemia","enrollment":419},{"nctId":"NCT02554942","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":28},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT01892202","phase":"","title":"A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Anemia","enrollment":""},{"nctId":"NCT00077766","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":313},{"nctId":"NCT02002039","phase":"PHASE2, PHASE3","title":"Neuroprotective Role of Erythropoietin in Perinatal Asphyxia","status":"COMPLETED","sponsor":"Sheri Kashmir Institute of Medical Sciences","startDate":"2012-06","conditions":"Perinatal Asphyxia","enrollment":100},{"nctId":"NCT00882713","phase":"PHASE3","title":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":202},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00546481","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":80},{"nctId":"NCT02263833","phase":"","title":"An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"Kidney Disease, Chronic","enrollment":748},{"nctId":"NCT01450878","phase":"PHASE3","title":"Renal Graft Function After Treatment With Erythropoietin (EPO)","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2011-12","conditions":"Ischemia","enrollment":6},{"nctId":"NCT00362414","phase":"PHASE2","title":"Beta-hCG + Erythropoietin in Acute Stroke","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-08","conditions":"Acute Stroke","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["erythropoietin, epoetin","NeoRecormon"],"phase":"phase_3","status":"active","brandName":"erythropoietin beta","genericName":"erythropoietin beta","companyName":"University of Cambridge","companyId":"university-of-cambridge","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erythropoietin beta stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}